Sign In
Buy MD
Mednax Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $0.370 |
| EPS actual | $0.440 |
| EPS Surprise | 18.92% |
| Revenue estimate | 465.828M |
| Revenue actual | 476.196M |
| Revenue Surprise | 2.23% |
| Release date | Feb 19, 2026 |
| EPS estimate | $0.530 |
| EPS actual | $0.500 |
| EPS Surprise | -5.66% |
| Revenue estimate | 486.228M |
| Revenue actual | 493.771M |
| Revenue Surprise | 1.55% |
| Release date | Nov 03, 2025 |
| EPS estimate | $0.460 |
| EPS actual | $0.670 |
| EPS Surprise | 45.65% |
| Revenue estimate | 486.23M |
| Revenue actual | 492.875M |
| Revenue Surprise | 1.37% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.420 |
| EPS actual | $0.530 |
| EPS Surprise | 26.19% |
| Revenue estimate | 473.669M |
| Revenue actual | 468.844M |
| Revenue Surprise | -1.02% |
Last 4 Quarters for Mednax
Below you can see how MD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 05, 2025 |
| Price on release | $12.92 |
| EPS estimate | $0.420 |
| EPS actual | $0.530 |
| EPS surprise | 26.19% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $12.40 |
| Jul 31, 2025 | $12.25 |
| Aug 01, 2025 | $11.98 |
| Aug 04, 2025 | $12.30 |
| Aug 05, 2025 | $12.92 |
| Aug 06, 2025 | $14.44 |
| Aug 07, 2025 | $14.48 |
| Aug 08, 2025 | $14.33 |
| Aug 11, 2025 | $14.12 |
| 4 days before | 4.19% |
| 4 days after | 9.29% |
| On release day | 11.76% |
| Change in period | 13.87% |
| Release date | Nov 03, 2025 |
| Price on release | $21.08 |
| EPS estimate | $0.460 |
| EPS actual | $0.670 |
| EPS surprise | 45.65% |
| Date | Price |
|---|---|
| Oct 28, 2025 | $17.84 |
| Oct 29, 2025 | $17.87 |
| Oct 30, 2025 | $17.39 |
| Oct 31, 2025 | $16.97 |
| Nov 03, 2025 | $21.08 |
| Nov 04, 2025 | $21.44 |
| Nov 05, 2025 | $21.69 |
| Nov 06, 2025 | $21.82 |
| Nov 07, 2025 | $21.93 |
| 4 days before | 18.16% |
| 4 days after | 4.03% |
| On release day | 1.71% |
| Change in period | 22.93% |
| Release date | Feb 19, 2026 |
| Price on release | $19.30 |
| EPS estimate | $0.530 |
| EPS actual | $0.500 |
| EPS surprise | -5.66% |
| Date | Price |
|---|---|
| Feb 12, 2026 | $21.07 |
| Feb 13, 2026 | $21.52 |
| Feb 17, 2026 | $21.71 |
| Feb 18, 2026 | $21.97 |
| Feb 19, 2026 | $19.30 |
| Feb 20, 2026 | $18.82 |
| Feb 23, 2026 | $19.74 |
| Feb 24, 2026 | $20.06 |
| Feb 25, 2026 | $19.90 |
| 4 days before | -8.40% |
| 4 days after | 3.11% |
| On release day | -2.49% |
| Change in period | -5.55% |
| Release date | May 05, 2026 |
| Price on release | $20.83 |
| EPS estimate | $0.370 |
| EPS actual | $0.440 |
| EPS surprise | 18.92% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $22.31 |
| Apr 30, 2026 | $22.51 |
| May 01, 2026 | $22.75 |
| May 04, 2026 | $22.41 |
| May 05, 2026 | $20.83 |
| May 06, 2026 | $22.21 |
| May 07, 2026 | $22.93 |
| May 08, 2026 | $23.51 |
| May 11, 2026 | $23.37 |
| 4 days before | -6.63% |
| 4 days after | 12.19% |
| On release day | 6.63% |
| Change in period | 4.75% |
Mednax Earnings Call Transcript Summary of Q1 2026
Pediatrix reported a strong Q1 2026 with adjusted EBITDA of $58 million driven by top-line growth and pricing gains that more than offset modest volume declines. Same-unit revenue grew just under 3% and pricing increased ~4%, supported by improved RCM cash collections, contract admin fees, favorable payer mix and higher acuity in neonatology. Q1 used seasonal cash (operating cash flow -$130M) for incentive and benefit payments; the company ended the quarter with ~$200M cash and net debt of ~ $385M (net leverage ~1.3x at midpoint of guidance). Management reaffirmed full-year adjusted EBITDA guidance of $280M–$300M and expects the remaining three quarters to be fairly ratable. Management emphasized a strategic focus on data-driven care quality (new senior hires in quality and AI) and sees opportunities to expand core services and tele/remote offerings. No material one-time items were called out for Q2; recent smaller acquisitions have performed ahead of expectations. Key risks flagged include potential delayed impacts from changes in tax subsidy dynamics and hospital/system volume pressures, although no current adverse trends have been observed in Pediatrix’s footprint.
